Abstract:Background & aims: Bile acid nuclear receptor farnesoid X receptor (FXR) is a key molecular mediator of many metabolic processes, including the regulation of bile acid, lipid and glucose homeostasis. A significant component of FXR-mediated events essential to its biological activity is attributed to induction of the enteric endocrine hormone fibroblast growth factor (FGF)19 or its rodent ortholog, FGF15. In this report, we compared the properties of human FGF19 and murine FGF15 in the regulation of hepatocarcinogenesis and metabolism in various mouse models of disease. Methods: Tumorigenicity was assessed in three mouse models (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient) following continuous exposure to FGF19 or FGF15 via adeno-associated viral-mediated gene delivery. Glucose, hemoglobin A1c and β-cell mass were characterized in db/db mice. Oxygen consumption, energy expenditure, and body composition were evaluated in diet-induced obese mice. Serum levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase were assessed in Mdr2-deficient mice. Expression profiles of genes encoding key proteins involved in bile acid synthesis and hepatocarcinogenesis were also determined. Results: Both FGF15 and FGF19 hormones repressed bile acid synthesis (p<0.001 for both). However, murine FGF15 lacked the protective effects characteristic of human FGF19 in db/db mice with overt diabetes, such as weight-independent HbA1c-lowering and β-cell-protection. Unlike FGF19, FGF15 did not induce hepatocellular carcinomas (HCC) in three mouse models of metabolic diseases (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient mice), even at supra-pharmacological exposure levels. Conclusions: Fundamental species-associated differences between FGF19 and FGF15 may restrict the relevance of mouse models for the study of the FXR/FGF19 pathway, and underscore the importance of clinical assessment of this pathway, with respect to both safety and efficacy in humans. Lay summary: Activation of the nuclear receptor, FXR, leads to the production of a hormone called fibroblast growth factor 19 (FGF19) and subsequently regulation of multiple metabolic processes. Synthetic activators of FXR have been recently approved or are currently in clinical development for treatment of chronic liver diseases, including primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The safety of these activators was partly assessed in mice exposed for prolonged periods of time. However, the results of this study show that mouse FGF15 and human FGF19 exhibit fundamentally different biological activities in mice. This could raise the concern of relying on rodent models for safety assessment of FXR activators. The potential risk of HCC development in patients treated with FXR agonists may need to be monitored.

Deletion of Ifn Gamma Enhances Hepatocarcinogenesis in Fxr Knockout Mice

Hepatocarcinogenesis in FXR−/− Mice Mimics Human HCC Progression That Operates Through HNF1α Regulation of FXR Expression

Distinct Role of Interleukin-6 and Tumor Necrosis Factor Receptor-1 in Oval Cell- Mediated Liver Regeneration and Inflammation-Associated Hepatocarcinogenesis

IFNγ‐mediated repression of system xc− drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells

Hnf6 Promotes Tumor Growth In Colorectal Cancer And Enhances Liver Metastasis In Mouse Model

Pregnane X receptor (PXR) deficiency promotes hepatocarcinogenesis via induction of Akr1c18 expression and prostaglandin F 2α (PGF 2α ) levels

Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.

Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes

Farnesoid X Receptor Associates with Β-Catenin and Inhibits Its Activity in Hepatocellular Carcinoma

Peroxisome Proliferator Activated Receptor Alpha Inhibits Hepatocarcinogenesis Through Mediating NF-κB Signaling Pathway.

Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma

Noncanonical Farnesoid X Receptor Signaling Inhibits Apoptosis and Impedes Liver Fibrosis

Altered ethanol metabolism and increased oxidative stress enhance alcohol-associated liver injury in farnesoid X receptor-deficient mice

Forced Expression of Hepatocyte-Specific Fibroblast Growth Factor 21 Delays Initiation of Chemically Induced Hepatocarcinogenesis.

The Critical Role of Myeloid-Derived Suppressor Cells and FXR Activation in Immune-Mediated Liver Injury.

Deletion of Interleukin-6 in Monocytes/macrophages Suppresses the Initiation of Hepatocellular Carcinoma in Mice

Mice Lacking FXR Are Susceptible to Liver Ischemia-Reperfusion Injury

Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15

Deletion of HNF1α in Hepatocytes Results in Fatty Liver‐related Hepatocellular Carcinoma in Mice

Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency

FXR Acts As a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.